TIS 0.00% 0.0¢ tissue therapies limited

very hot tip, page-2

  1. 4,460 Posts.
    From 11 March....Change of CEO and Chief Scientist Interest
    Biomedical company, Tissue Therapies Limited (ASX: TIS) today announced that the
    CEO, Dr Steven Mercer has increased the shareholding of a related entity of which he is
    Trustee by another 46,500 shares in Tissue Therapies. These shares were bought on the
    open market and are reported in the attached Appendix 3Y. This brings the total Tissue
    Therapies shareholding of Dr Mercer’s related entity to 138,000 shares bought on the open
    market.
    The Chief Scientific Officer of Tissue Therapies, Professor Zee Upton and related entities
    have also recently increased their Tissue Therapies shareholding by open market purchases
    of an additional 74,000 shares, these purchases being completed on 28 February 2008.
    This brings the total shareholding of Professor Upton and related entities to 1,475,276
    shares (4.76% of total issued equity).
    ENDS
    Further information: Dr Steven Mercer
    CEO, Tissue Therapies Limited
    Telephone: 07 3839 9938
    Email: [email protected]
    About Tissue Therapies Limited
    Tissue Therapies Limited is an Australian company developing biomedical technologies for
    wound healing, tissue and various cell culture applications.
    The Company has worldwide exclusive rights to commercialise VitroGro®, a versatile growth
    factor based technology developed by tissue engineering experts at the Institute for Health
    and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has
    particular commercial applications in wound healing, tissue regeneration, stem cell therapies
    and other cell culture uses.
    Based on its VitroGro® technology, Tissue Therapies is developing more effective medical
    treatments for wounds and burns, integration of orthopaedic and medical implants, and other
    applications such as cosmeceuticals.
    Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian
    cells for emerging cell-based therapies, along with research and industrial cell culture
    markets internationally.
    More information: www.tissuetherapies.com
 
watchlist Created with Sketch. Add TIS (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.